411 related articles for article (PubMed ID: 33028694)
1. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Chen Z; Chen Y; Peng L; Wang X; Tang N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
[TBL] [Abstract][Full Text] [Related]
2. 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
Pan B; Chen Z; Zhang X; Wang Z; Yao Y; Wu X; Qiu J; Lin H; Yu L; Tu H; Tang N
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37316264
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
4. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
5. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
8. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
13. HBV induced hepatocellular carcinoma and related potential immunotherapy.
Jia L; Gao Y; He Y; Hooper JD; Yang P
Pharmacol Res; 2020 Sep; 159():104992. PubMed ID: 32505833
[TBL] [Abstract][Full Text] [Related]
14. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.
Tanaka T; Koga H; Suzuki H; Iwamoto H; Sakaue T; Masuda A; Nakamura T; Akiba J; Yano H; Torimura T; Kawaguchi T
Hepatol Int; 2024 Jun; 18(3):984-997. PubMed ID: 37553470
[TBL] [Abstract][Full Text] [Related]
16. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
[TBL] [Abstract][Full Text] [Related]
18. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
20. Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma.
Guo L; Li H; Fan T; Ma Y; Wang L
Life Sci; 2021 Aug; 279():119359. PubMed ID: 33753114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
